Бронхиальная астма и ожирение: поиск терапевтических моделей
Аннотация
Все большее внимание экспертов уделяется фенотип-обоснованному подходу к лечению пациентов с бронхиальной астмой (БА). Одним из основных клинических фенотипов является сочетание БА и избыточной массы тела, а в некоторых случаях – ожирения. Ряд клинических особенностей этого тандема объясняется результатами молекулярно-генетических исследований. Активный поиск взаимосвязей между фенотипом, генотипом и механизмом развития заболевания позволит разработать эффективный терапевтический алгоритм, наиболее прогностически оправданный у данной подгруппы пациентов.
Об авторах
Д. С. Фомина
ГБОУ ДПО "Российская медицинская академия последипломного образования" Минздрава России: 125993, Москва, ул. Баррикадная, 2 / 1
ГБУЗ "Городская клиническая больница No52" Департамента здравоохранения Москвы: 123182, Москва, ул. Пехотная, 3
Россия
Россия
к. м. н., доцент кафедры клинической аллергологии ГБОУ ДПО "Российская медицинская академия последипломного образования" Минздрава России, зав. аллергологическим отделением ГБУЗ "Городская клиническая больница No 52" ДЗ Москвы; тел.: (499) 196-19-54
Л. А. Горячкина
ГБОУ ДПО "Российская медицинская академия последипломного образования" Минздрава России: 125993, Москва, ул. Баррикадная, 2 / 1
Россия
Россия
д. м. н., профессор, зав. кафедрой клинической аллергологии ГБОУ ДПО "Российская медицинская академия последипломного образования" Минздрава России; тел.: (499) 196-19-54
Ю. Г. Алексеева
ГБУЗ "Городская клиническая больница No52" Департамента здравоохранения Москвы: 123182, Москва, ул. Пехотная, 3
Россия
Россия
врач аллерголог-иммунолог ГБУЗ "Городская клиническая больница No 52" ДЗ Москвы; тел.: (499) 196-29-88
Е. Н. Бобрикова
ГБУЗ "Филиал No2 Городская поликлиника No62" Департамента здравоохранения Москвы: 125083, Москва, ул. Юннатов, 12
Россия
Россия
врач аллерголог-иммунолог ГБУЗ "Филиал No 2 Городская поликлиника No 62" ДЗ Москвы, главный внештатный аллерголог САО Москвы; тел.: (962) 962-00-96
Список литературы
1. Global Initiative for Asthma (GINA) Guidelines 2014. http://www.ginasthma.org
2. Luskin A.T. What the asthma end points we know and love do and do not tell us. J. Allergy Clin. Immunol. 2005; 115: S539–S545.
3. Busse W.W., Lemanske R.F. Jr. Asthma. N. Engl. J. Med. 2001; 344: 350–362.
4. Claessen H., Brenner H., Drath C., Arndt V. Repeated measures of body mass index and risk of health related outcomes. Eur. J. Epidemiol. 2012; 27 (3): 215–224.
5. Dixon A.E. An Official American Thoracic Society Workshop Report: Obesity and asthma. Proc. Am. Thorac. Soc. 2010; 7: 325–335.
6. Burgess J.A., Walters E.H., Byrnes G.B. et al. Childhood adiposity predicts adult-onset current asthma in females: a 25-yr prospective study. Eur. Respir. J. 2007; 29: 668–675.
7. Taylor B., Mannino D., Brownet C. et al. Body mass index and asthma severity in the National Asthma Survey. Thorax. 2008; 63 (1): 14–20.
8. Aaron S.D., Fergusson D., Dent R. et al. Effect of weight reduction on respiratory function and airway reactivity in obese women. Chest. 2004; 125: 2046–2052.
9. Moreira A., Bonini M., Garcia-Larsen V. et al. Weight loss interventions in asthma: EAACI Evidence-Based Clinical Practice Guideline (Part I). Allergy. 2013; 68: 425–439.
10. Gray D.S., Fujioka K. Use of relative weight and Body Mass Index for the determination of adiposity. J. Clin. Epidemiol. 1991; 44 (6): 545–550.
11. Flegal K.M., Ogden C.L., Wei R. et al. Prevalence of overweight in US children: comparison of US growth charts from the Centers for Disease Control and Prevention with other reference values for body mass index. Am. J. Clin. Nutr. 2001; 73 (6): 1086–1093. PMID 11382664.
12. Shore S.A. Obesity and asthma: possible mechanisms. J. Allergy Clin. Immunol. 2008; 121: 1087–1093. Quiz 94–95.
13. Hallstrand T.S., Fischer M.E., Wurfel M.M. et al. Genetic pleiotropy between asthma and obesity in a communitybased sample of twins. J. Allergy Clin. Immunol. 2005; 116: 1235–1241.
14. Beuther D.A., Weiss S.T., Sutherland E.R. Obesity and asthma. Am. J. Respir. Crit. Care Med. 2006; 174: 112–119.
15. Canoz M., Erdenen F., Uzun H. et al., The relationship of inflammatory cytokines with asthma and obesity. Clin. Invest. Med. 2008; 31 (6): E373–E379.
16. Sierra-Honigmann M.R., Nath A.K., Murakami C. et al. Biological action of leptin as an angiogenic factor. Science. 1998; 281 (5383): 1683–1686.
17. Sood A., Ford E.S., Camargo C.A. Jr. Association between leptin and asthma in adults. Thorax. 2006; 61 (4): 300–305.
18. Strissel K.J., Stancheva Z., Miyoshi H. et al. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes. 2007; 56: 2910–2918.
19. Alkhouri N., Gornicka A., Berk M.P. et al. Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J. Biol. Chem. 2010; 285: 3428–3438.
20. Abreu Velez A.M., Dejoseph L.M., Howard M.S. HAM56 and CD68 antigen presenting cells surrounding a sarcoidal granulomatous tattoo. N. Am. J. Med. Sci. 2011; 3: 475–477.
21. Sethi J.K., Vidal-Puig A.J. Thematic review series: Adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J. Lipid. Res. 2007; 48: 1253–1262.
22. Osborn O., Olefsky J.M. The cellular and signaling networks linking the immune system and metabolism in disease. Nat. Med. 2012; 18: 363–374.
23. Mantovani A., Sozzani S., Locati M. et al. Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002; 23: 549–555.
24. Sica A., Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J. Clin. Investig. 2012; 122: 787–795.
25. Mosser D.M. The many faces of macrophage activation. J. Leukoc. Biol. 2003; 73: 209–212.
26. Shore S.A., Lang J.E., Kasahara D.I. et al. Pulmonary responses to subacute ozone exposure in obese vs. lean mice. J. Appl. Physiol. 2009; 107 (5): 1445–1452.
27. Shore S.A. Obesity, airway hyperresponsiveness, and inflammation. J. Appl. Physiol. 2010; 108 (3): 735–743.
28. Fjeldborg K., Christiansen T., Bennetzen M. et al. The macrophage specific serum marker, soluble CD163, is increased in obesity and reduced after dietary induced weight loss. Obesity (Silver Spring). 2013; 21 (12): 2437–2443. DOI:10.1002/oby.20376.
29. Al-Daghri N.M., Al-Attas O.S., Bindahman L.S. et al. Soluble CD163 is associated with bodymass index and blood pressure in hypertensive obese Saudi patients. Eur. J. Clin. Invest. 2012, 42, 1221–1226.
30. Kristiansen M., Graversen J.H., Jacobsen C. et al. Identification of the haemoglobin scavenger receptor. Nature. 2001; 409: 198–201.
31. Theoharides T.C., Cochrane D.E. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 2004; 146: 1–12.
32. Chida Y., Hamer M., Steptoe A. A bidirectional relationship between psychosociall factors and atopic disorders: a systematic review and meta-analysis. Psychosom. Med. 2008; 70: 102–116.
33. Theoharides T.C., Enakuua S., Sismanopoulos N. et al. Stress contributes to asthma worsening through mast cell activation. Ann. Allergy Asthma Immunol. 2012; 109: 14–19.
34. Girodet P.O., Ozier A., Trian T. et al. Mast cell adhesion to bronchial smooth muscle in asthma specifically depends on CD51 and CD44 variant 6. Allergy. 2010; 65: 1004–1012.
35. Oh S.H., Park C.O., Wu W.H. et al. Corticotropin-releasing hormone downregulates IL-10 production by adaptive forkhead box protein 3-negative regulatory T-cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2012; 129: 151–159.
36. Dut R., Dizdar E.A., Birben E. et al. Oxidative stress and its determinants in the airways of children with asthma. Allergy. 2008; 63 (12): 1605–1609.
37. Sackesen C., Ercan H., Dizdar E. et al. A comprehensive evaluation of the enzymatic and nonenzymatic antioxidant systems in childhood asthma. J. Allergy Clin. Immunol. 2008; 122 (1): 78–85.
38. Ercan H., Birben E., Dizdar E.A. et al. Oxidative stress and genetic and epidemiologic determinants of oxidant injury in childhood asthma. J. Allergy Clin. Immunol. 2006; 118 (5): 1097–1104.
39. Lugogo N.L., Bappanad D., Kraft M. Obesity, metabolic dysregulation and oxidative stress in asthma. Biochim. Biophys. Acta. 2011; 1810 (11): 1120–1126.
40. Peters-Golden M., Swern A., Bird S.S. et al. Influence of body mass index on the response to asthma controller agents. Eur. Respir. J. 2006; 27: 495–503.
41. Beuther D.A., Sutherland E.R. Overweight, obesity, and incident asthma: a metaanalysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care Med. 2007; 175: 661–666.
42. Castro-Rodriguez J.A., Holberg C.J., Morgan W.J. et al. Increased incidence of asthmalike symptoms in girls who become overweight or obese during the school years. Am. J. Respir. Crit. Care Med. 2001; 163: 1344–1349.
43. Gold D.R., Damokosh A.I., Dockery D.W., Berkey C.S. Body-mass index as a predictor of incident asthma in a prospective cohort of children. Pediatr. Pulm. 2003; 36: 514–521.
44. Oddy W.H., Sherriff J.L., de Klerk N.H. et al. The relation of breastfeeding and body mass index to asthma and atopy in children: a prospective cohort study to age 6 years. Am. J. Public. Hlth. 2004; 94: 1531–1537.
45. Mamun A.A., Lawlor D.A., Alati R. et al. Increasing body mass index from age 5 to 14 years predicts asthma among adolescents: evidence from a birth cohort study. Int. J. Obes. 2007; 31: 578–583.
46. Kotani K., Tokunaga K., Fujioka S. et al. Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int. J. Obes. Relat. Metab. Disord. 1994; 18: 207–212.
47. Van Harmelen V., Reynisdottir S., Eriksson P. et al. Leptin secretion from subcutaneous and visceral adipose tissue in women. Diabetes. 1998; 47: 913–917.
48. Troisi R.J., Speizer F.E., Willett W.C. et al. Menopause, postmenopausal estrogen preparations, and the risk of adult-onset asthma. A prospective cohort study. Am. J. Respir. Crit. Care Med. 1995; 152: 1183–1188.
49. Jensen M.E., Collins C.E. The obesity phenotype in children with asthma. Pediatr. Respir. Rev. 2011; 12 (3): 152–159.
50. Camargo C.A. Jr, Boulet L.P., Sutherland E.R. et al. Body mass index and response to asthma therapy: Fluticasone propionate / salmeterol versus montelukast. J. Asthma. 2010; 47: 76–82.
51. Sutherland E.R., Lehman E.B., Teodorescu M., Wechsler M.E. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J. Allergy Clin. Immunol. 2009; 123: 1328–1334.
52. Peters-Golden M., Swern A., Bird S.S. et al. Influence of body mass index on the response to asthma controller agents. Eur. Respir. J. 2006; 27: 495–503.
53. Boulet L.P., Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir. Med. 2007; 101: 2240–2247.
54. Kazaks A., Uriu-Adams J.Y., Stern J.S., Albertson T.E. No significant relationship between exhaled nitric oxide and body mass index in people with asthma. J. Allergy Clin. Immunol. 2005; 116: 929–930.
55. Leung T.F., Li C.Y., Lam C.W. et al. The relation between obesity and asthmatic airway inflammation. Pediatr. Allergy Immunol. 2004; 15: 344–350.
56. Telenga E.D., Tideman S.W. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response. Allergy. 2012; 67: 1060–1068.
57. Haldar P., Pavord I.D., Shaw D.E. et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med. 2008; 178: 218–224.
58. Scott H.A., Gibson P.G., Garg M.L., Wood L.G. Airway inflammation is augmented byobesity and fatty acids in asthma. Eur. Respir. J. 2011; 38: 594–602.
59. Stream A.R., Sutherland E.R. Obesity and asthma disease phenotypes. Curr. Opin. Allergy Clin. Immunol. 2012; 12: 76–81.
60. Horrillo R., González-Périz A., Martínez-Clemente M. et al. 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J. Immunol. 2010; 184 (7): 3978–3987.
61. Chakrabarti S.K., Wen Y., Dobrian A.D. et al. Evidence for activation of inflammatory lipoxygenase pathways in visceral adipose tissue of obese Zucker rats. Am. J. Physiol. Endocrinol. Metab. 2011; 300 (1): E175–E187.
62. Sutherland E.R., Goleva E., Jackson L.P. et al. Vitamin D levels, lung function, and steroid response in adult asthma. Am. J. Respir. Crit. Care Med. 2010; 181 (7): 699–704.
63. Middleton E. Jr, Kandaswami C., Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease and cancer. Pharmacol. Rev. 2000; 52: 673–751.
64. Kimata M., Schchijo M., Miura T. et al. Effects of luteolin, quercetin and baicalein on immunoglobulin E-mediated mediator release from human cultured mast cells. Clin. Exp. Allergy. 1999; 30: 501–508.
65. Kempuraj D., Madhappan B., Christodoulou S. et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phosphorylation in human mast cells. Br. J. Pharmacol. 2005; 145: 934–944.
66. Deqiu Z., Kang L., Jiali Y. et al. Luteolin inhibits inflammatory response and improves insulin sensitivity in the endothelium. Biochimie. 2011; 93: 506–512.
Для цитирования:
Фомина Д.С., Горячкина Л.А., Алексеева Ю.Г., Бобрикова Е.Н. Бронхиальная астма и ожирение: поиск терапевтических моделей. Пульмонология. 2014;(6):94-102. https://doi.org/10.18093/0869-0189-2014-0-6-94-102
For citation:
Fomina D.S., Goryachkina L.A., Alekseeva Yu.G., Bobrikova E.N. Bronchial asthma and obesity: search for therapeutic models. PULMONOLOGIYA. 2014;(6):94-102. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-6-94-102
Просмотров: 935
Послать статью по эл. почте 